Abstracts tagged "OMERACT"

Abstract Number: 1361 • ACR Convergence 2020
Secukinumab Significantly Decreased Joint Synovitis Measured by Power Doppler Ultrasonography in Biologic-naïve Patients with Active Psoriatic Arthritis: Primary (12-Week) Results from a Randomized, Placebo-Controlled Phase III Study
Maria D’Agostino¹, Georg Schett², Alejandra López-Rdz³, Ladislav Šenolt⁴, Jose Maldonado-Cocco⁵, Ruben Burgos-Vargas⁶, Esperanza Naredo⁷, Philippe Carron⁸, Maarten Boers⁹, Anne-Marie Duggan¹⁰, Punit Goyanka¹¹ and Corine Gaillez¹², ¹Université Versailles Saint Quentin, Ambroise Paré Hospital, Paris, France, ²Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany, ³Dermatológico Country, Jalisco, Mexico, ⁴Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁵University of Buenos Aires School of Medicine, Buenos Aires, Argentina, ⁶Department of Rheumatology, General Hospital of Mexico, Ciudad de Mexico, Mexico, ⁷Department of Rheumatology, Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz, IIS Fundación Jiménez Díaz and Universidad Autónoma de Madrid, Madrid, Spain, ⁸Department of Rheumatology, University Hospital Ghent, Ghent, Belgium, ⁹Department of Epidemiology & Biostatistics, Amsterdam Rheumatology and Immunology Center, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ¹⁰Novartis Ireland Limited, Dublin, Ireland, ¹¹Novartis Healthcare Pvt. Ltd., Hyderabad, India, ¹²Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Power Doppler (PD) ultrasonography (PDUS) is a sensitive non-invasive imaging technology used to assess joint synovitis and enthesitis of psoriatic arthritis (PsA) in clinical…
Abstract Number: 1886 • ACR Convergence 2020
Measuring Physical Activity in AxSpA:Content Validity and Measurement Properties of the New AxSpA-SQUASH
Marllies Carbo¹, Davy Paap², Fiona Maas¹, Mark Siderius³, Hendrika Bootsma¹, Freke Wink³, Suzanne Arends³ and Anneke Spoorenberg³, ¹University Medical Centre Groningen, Groningen, Netherlands, ², Department of Rehabilitation Medicine, University of Medical Centre Groningen, Groningen, Netherlands, ³University Medical Centre Groningen and Medical centre Leeuwarden, Groningen, Netherlands
Background/Purpose: The ASAS-EULAR recommendations for management of axial Spondyloarthritis (axSpA) includes that patients should be encouraged to exercise. There is no validated instrument for measuring…
Abstract Number: 1939 • ACR Convergence 2020
Definitions and Reliability Assessment of Chronic Ultrasound Lesions of the Axillary Artery in Giant Cell Arteritis: A Study from the OMERACT Large Vessel Vasculitis Ultrasound Working Group
Valentin Schaefer¹, Stavros Chrysidis², Greta Carrara³, Wolfgang Schmidt⁴, George A. Bruyn⁵, Bhaskar Dasgupta⁶, Eugenio De Miguel⁷, Andreas Diamantopoulos⁸, Christina Duftner⁹, Ulrich Fredberg¹⁰, Berit Nielsen¹¹, Wolfgang Hartung¹², Alojzija Hocevar¹³, Annamaria Iagnocco¹⁴, Aaron Juche⁴, Tanaz Kermani¹⁵, Tove Lorenzen¹⁶, Pierluigi Macchioni¹⁷, Marcin Milchert¹⁸, Uffe Døhn¹⁹, Sara Monti²⁰, Chetan Mukhtyar²¹, Cristina Ponte²², Carlo Scire²³, Lene Terslev²⁴, Luca Seitz²⁵ and Christian Dejaco²⁶, ¹Clinic of Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, ²Sydvestjysk Sygehus Esbjerg, Esbjerg, Denmark, ³Epidemiology Unit, Italian Society for Rheumatology, Milan, Italy, ⁴Immanuel Krankenhaus Berlin Buch, Berlin, Germany, ⁵Rheumatology, Reumakliniek Lelystad, Lelystad, Netherlands, ⁶Rheumatology, Mid and South Essex University Hospital NHS Foundation Trust, Southend University Hospital, United Kingdom, Westcliff on sea, England, United Kingdom, ⁷Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, ⁸Martina Hansens Hospital, Baerum, Norway, ⁹Medical University Innsbruck, Innsbruck, Austria, ¹⁰Silkeborg Regional Hospital, Silkeborg, Denmark, ¹¹Aarhus University Hospital, Aarhus, Denmark, ¹²Asklepios Klinik Bad Abbach, Bad Abbacg, Germany, ¹³University Medical Center, Rheumatology, Ljubljana, LJUBLJANA, Slovenia, ¹⁴Università degli Studi di Torino, Academic Rheumatology Centre, Turin, Italy, ¹⁵David Geffen School of Medicine / University of California, Los Angeles, CA, ¹⁶Copenhagen Center for Arthritis Research, Copenhagen, Denmark, ¹⁷Unità Operativa di Reumatologia/Arcispedale S. Maria Nuova, Reggio Emilia, Italy, ¹⁸Pomeranian Medical University, Szczecin, Poland, ¹⁹Center for Rheumatology and Spine Diseasesand COPECARE, Copenhagen, Denmark, ²⁰Fondazione IRCCS Policlinico S Matteo, University of Pavia, Pavia, Italy, ²¹Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom, ²²Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal, ²³University of Ferrara, Ferrara, Italy, ²⁴Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup., Copenhagen, Denmark, ²⁵Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Switzerland, Bern, Switzerland, ²⁶South Tyrol Health Trust, Hospital of Bruneck, Bruneck, Italy
Background/Purpose: The OMERACT Ultrasound (US) large vessel vasculitis task force has recently defined the US appearance of normal axillary arteries (AA) and the key elementary…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.